Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc > old news releases
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by go4futureon Jan 25, 2010 10:43am
440 Views
Post# 16714668

RE: Re: old news releases

RE: Re: old news releasesLets stick to the facts.... I'd say Lux Biosciences has considerable future expectations and investments at stake with their Isotechnika relationship considering that virtually all of their future pipeline LX211 (Luveniq), LX12, LX13 & LX14 involves Voclosporin.

https://www.luxbio.com/pipeline.htm
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities